Skip to main content
Year archive

4SC AG — 2019 filings

All 45 regulatory filings released by 4SC AG (VSC) in 2019, sourced directly from the official regulator.

45 Filings
2019 Period
2019 filings (45)
Filing Released Lang
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-12-19 English
Report Publication Announcement 2019
Report Publication Announcement
2019-12-19 English
Report Publication Announcement 2019
Report Publication Announcement
2019-12-19 English
Datum:19.12.2019
Report Publication Announcement
2019-12-19 German
4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
Legal Proceedings Report
2019-12-13 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-11-20 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements
2019-11-19 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2019-11-14 English
4SC AG secures circa EUR 22.4 million from a capital increase
Share Issue/Capital Change
2019-11-12 English
Q3 statement / Q3 financial report 2019
Interim / Quarterly Report 9M 2019
2019-10-30 English
4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma
Report Publication Announcement
2019-10-21 English
4SC provides Q3 business update and outlook
Earnings Release Q3 2019
2019-10-17 English
4SC and Netherlands Cancer Institute Collaborate on Clinical Evaluation of Domatinostat in the Neoadjuvant Setting in Melanoma
Regulatory Filings
2019-10-16 English
4SC AG: Conference call to be hosted on 17 October 2019 to present the Q3 Announcement 2019
Regulatory Filings
2019-10-10 English
4SC AG resolves to issue new shares; Santo and ATS undertake to subscribe / buy the new shares
Capital/Financing Update
2019-10-07 English
4SC AG: First domatinostat combination data from Phase Ib/II SENSITIZE study presented at ESMO
Regulatory Filings
2019-09-30 English
4SC AG: Pivotal RESMAIN study of resminostat in CTCL: update at the EORTC CLTF meeting 2019 in Athens
Regulatory Filings
2019-09-27 English
4SC AG: Poster presentations at ESMO Congress 2019
Regulatory Filings
2019-09-23 English
4SC AG: 8 upcoming conferences
Regulatory Filings
2019-08-28 English
Half-yearly financial report 2019
Interim / Quarterly Report H1 2019
2019-08-14 English
4SC AG receives milestone payment from Link Health - Link Health initiates Phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma
Regulatory Filings
2019-08-13 English
4SC AG provides Q2 and H1 2019 update
Earnings Release H1 2019
2019-08-08 English
4SC AG: Conference call to be hosted on 8 August 2019 to present the half-year report 2019
Report Publication Announcement
2019-08-01 English
4SC AG: Positive safety review of Phase Ib/II EMERGE study of domatinostat + avelumab in gastrointestinal cancer
Regulatory Filings
2019-07-25 English
4SC AG: Positive safety review of Phase Ib/II SENSITIZE study of domatinostat + pembrolizumab in melanoma
Legal Proceedings Report
2019-07-11 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2019-07-02 English
4SC AG secures EUR 11 million from capital increase
Share Issue/Capital Change
2019-06-28 English
4SC AG announces subscription price for new shares from current capital increase
Capital/Financing Update
2019-06-21 English
4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat and domatinostat
Capital/Financing Update
2019-06-11 English
4SC AG: 4 upcoming conferences
Report Publication Announcement
2019-05-16 English
4SC provides Q1 2019 update
Earnings Release Q1 2019
2019-04-18 English
Q1 statement / Q1 financial report 2019
Management Reports
2019-04-18 English
4SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 24.05.2019 in Planegg-Martinsried mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2019-04-12 German
Datum:11.04.2019
Management Reports
2019-04-11 German
4SC AG: Domatinostat's mode of action in Merkel cell carcinoma
Environmental & Social Information
2019-04-08 English
4SC AG: Dynavax's SD-101 and 4SC's Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models
Regulatory Filings
2019-04-01 English
Annual financial report 2018
Annual Report FY 2018
2019-03-22 English
Annual financial report 2018
Annual Report FY 2018
2019-03-22 German
4SC AG provides results for financial year 2018 and outlook
Earnings Release FY 2018
2019-03-20 English
4SC AG: Conference call to be hosted on 20 March 2019 to present the annual report 2018
Report Publication Announcement
2019-03-13 English
4SC AG: 9 upcoming conferences and roadshows
Regulatory Filings
2019-03-07 English
4SC AG: First patient enrolled in Phase II study EMERGE of domatinostat (4SC-202) in gastrointestinal cancer
Legal Proceedings Report
2019-02-06 English
4SC AG: First patient enrolled in 3rd dose cohort of Phase Ib/II study SENSITIZE
Regulatory Filings
2019-01-30 English
4SC's pivotal RESMAIN study of resminostat in CTCL receives second positive safety review
Legal Proceedings Report
2019-01-28 English
4SC AG: 4SC's domatinostat (4SC-202) begins Phase II gastrointestinal cancer clinical trial
Regulatory Filings
2019-01-14 English